Wealthquest Corp Takes Position in Amedisys, Inc. (NASDAQ:AMED)

Wealthquest Corp bought a new stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 13,516 shares of the health services provider's stock, valued at approximately $1,310,000.A number of other hedge funds also recently modified their holdings of AMED. Norges Bank purchased a new stake in shares of Amedisys in the fourth quarter valued at $83,061,000. Pentwater Capital Management LP raised its holdings in shares of Amedisys by 178.3% during the fourth quarter. Pentwater Capital Management LP now owns 1,180,000 shares of the health services provider's stock worth $107,132,000 after acquiring an additional 756,000 shares in the last quarter. AQR Arbitrage LLC raised its holdings in shares of Amedisys by 59.1% during the fourth quarter. AQR Arbitrage LLC now owns 471,965 shares of the health services provider's stock worth $42,812,000 after acquiring an additional 175,311 shares in the last quarter. Toronto Dominion Bank purchased a new stake in shares of Amedisys during the fourth quarter worth $15,801,000. Finally, CIBRA Capital Ltd raised its holdings in shares of Amedisys by 359.7% during the first quarter. CIBRA Capital Ltd now owns 216,775 shares of the health services provider's stock worth $20,080,000 after acquiring an additional 169,616 shares in the last quarter. Hedge funds and other institutional investors own 94.36% of the company's stock. Amedisys Price PerformanceShares of NASDAQ:AMED opened at $98.69 on Thursday. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.27. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.77. The business has a fifty day simple moving average of $96.55 and a 200 day simple moving average of $94.07. The firm has a market cap of $3.24 billion, a price-to-earnings ratio of 38.40, a P/E/G ratio of 1.33 and a beta of 0.94. Amedisys (NASDAQ:AMED - Get Free Report) last posted its earnings results on Tuesday, July 29th. The health services provider reported $1.54 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.15. Amedisys had a return on equity of 13.09% and a net margin of 3.56%. The company had revenue of $621.86 million for the quarter, compared to analyst estimates of $614.61 million. During the same period last year, the company earned $0.98 earnings per share. The business's revenue was up 5.2% compared to the same quarter last year. As a group, sell-side analysts predict that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year. Wall Street Analysts Forecast GrowthSeveral analysts recently issued reports on AMED shares. Royal Bank Of Canada reiterated an "outperform" rating and set a $100.00 price objective on shares of Amedisys in a report on Wednesday, April 16th. Wall Street Zen lowered Amedisys from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 24th.Read Our Latest Research Report on AMEDAbout Amedisys (Free Report)Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.Recommended StoriesFive stocks we like better than AmedisysHigh Dividend REITs: Are They an Ideal Way to Diversify?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?What Are the U.K. Market Holidays? How to Invest and TradeHow Marvell Went From Short Target to Breakout StarProcter & Gamble NYSE: PG Pulls Back After Shaky GuidancePalo Alto Networks: The All‑in‑One Cybersecurity PowerhouseThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Amedisys Right Now?Before you consider Amedisys, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.While Amedisys currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here